Katherine C. Fitch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Katherine C. Fitch has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abrar A. Qureshi
Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, USA
1 shared publication C. M. Johnson
Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RI
1 shared publication- Emma S. Ryan
Department of Obstetrics and Gynecology Indiana University Indianapolis Indiana USA
1 shared publication - Haley A. Moss
Division of Hematology and Oncology, Durham VA Healthcare System , Durham, NC 27705
1 shared publication J. F. Merola
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
1 shared publication- Jennifer K. Plichta
Department of Surgery, Duke University Medical Center, Durham, NC
1 shared publication
Latest Publications
Preferences of BRCA mutation carriers for attributes of risk‐reducing surgical options for breast and ovarian cancer
Background: Risk‐reducing surgeries are the most effective strategies for cancer prevention in patients with germline pathogenic variants in the BRCA1 / BRCA2 genes; these surgeries are associated with early menopause, loss of childbearing potential, and cosmetic effects. The authors assessed women's preferences for tradeoffs related to risk‐reducing surgical decision making. Methods: Carriers of pathogenic mutations in BRCA1/BRCA2 aged 25–50 years without a personal history of breast, ovarian, peritoneal, or tubal cancer were recruited to complete one of four discrete choice surveys based on their age (younger than 40 years or 40 years and older) and BRCA mutation status (BRCA1 or BRCA2). Participants responded to a series of choices between a do‐nothing strategy and two profiles representing various effects of surgical options on menopause, childbearing potential (those younger than 40 years only), breast appearance, and 10‐year and lifetime risks of breast and ovarian cancer. A conditional logit model was used to quantify participants' choices as a function of surgical options and outcomes. Results: In total, 298 participants completed the survey. Each cohort younger than BRCA1 mutations favored RRSO at age 40 years but with a 56.6% choice probability of delayed RRSO after ages 35–40 years, as recommended by National Comprehensive Cancer Network guidelines. The cohort aged 40 and older with BRCA2 mutations favored RRSO at age 40, 45, or 50 years fairly equally, with a 33.0% choice probability of guideline‐nonconcordant RRSO timing. All cohorts favored mastectomy at younger ages and with reconstruction versus no mastectomy. Conclusions: These findings demonstrate the heterogeneity of preferences and support individualized discussion of treatment goals relating to risk‐reducing surgical planning.
Preferences of BRCA mutation carriers for attributes of risk‐reducing surgical options for breast and ovarian cancer
Background: Risk‐reducing surgeries are the most effective strategies for cancer prevention in patients with germline pathogenic variants in the BRCA1 / BRCA2 genes; these surgeries are associated with early menopause, loss of childbearing potential, and cosmetic effects. The authors assessed women's preferences for tradeoffs related to risk‐reducing surgical decision making. Methods: Carriers of pathogenic mutations in BRCA1/BRCA2 aged 25–50 years without a personal history of breast, ovarian, peritoneal, or tubal cancer were recruited to complete one of four discrete choice surveys based on their age (younger than 40 years or 40 years and older) and BRCA mutation status (BRCA1 or BRCA2). Participants responded to a series of choices between a do‐nothing strategy and two profiles representing various effects of surgical options on menopause, childbearing potential (those younger than 40 years only), breast appearance, and 10‐year and lifetime risks of breast and ovarian cancer. A conditional logit model was used to quantify participants' choices as a function of surgical options and outcomes. Results: In total, 298 participants completed the survey. Each cohort younger than BRCA1 mutations favored RRSO at age 40 years but with a 56.6% choice probability of delayed RRSO after ages 35–40 years, as recommended by National Comprehensive Cancer Network guidelines. The cohort aged 40 and older with BRCA2 mutations favored RRSO at age 40, 45, or 50 years fairly equally, with a 33.0% choice probability of guideline‐nonconcordant RRSO timing. All cohorts favored mastectomy at younger ages and with reconstruction versus no mastectomy. Conclusions: These findings demonstrate the heterogeneity of preferences and support individualized discussion of treatment goals relating to risk‐reducing surgical planning.
- 29 January 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (2) , 379-380
Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
Psoriasis (PsO) and psoriatic arthritis (PsA) are inflammatory disorders. Circulating biomarkers of inflammation such as interleukin‐6 (IL‐6), Tumor Necrosis Factor‐α (TNF‐α), and C‐reactive protein (CRP) have been associated with disease severity and progression of PsO and PsA. Adiponectin and leptin are adipose derived cytokines, recognized as key regulator of body weight and metabolism2. Whether circulating levels of these inflammatory and metabolic biomarkers may predict the risk of PsA in psoriasis populations remains unclear.
- 29 January 2019
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 181 (2) , 379-380
Plasma levels of tumour necrosis factor‐α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis
Psoriasis (PsO) and psoriatic arthritis (PsA) are inflammatory disorders. Circulating biomarkers of inflammation such as interleukin‐6 (IL‐6), Tumor Necrosis Factor‐α (TNF‐α), and C‐reactive protein (CRP) have been associated with disease severity and progression of PsO and PsA. Adiponectin and leptin are adipose derived cytokines, recognized as key regulator of body weight and metabolism2. Whether circulating levels of these inflammatory and metabolic biomarkers may predict the risk of PsA in psoriasis populations remains unclear.